scholarly journals Correlation of Hydronephrosis Index to Society of Fetal Urology Hydronephrosis Scale

2009 ◽  
Vol 2009 ◽  
pp. 1-4 ◽  
Author(s):  
Krishnan Venkatesan ◽  
Joel Green ◽  
Steven R. Shapiro ◽  
George F. Steinhardt
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Quantitative Measure ◽  
Clinical Decision ◽  
Grade Ii ◽  
Grade Average ◽  
Calculated Average ◽  
Over Time ◽  
Grade Iii

Purpose. We seek to correlate conventional hydronephrosis (HN) grade and hydronephrosis index (HI).Methods. We examined 1207 hydronephrotic kidneys by ultrasound. HN was classified by Society of Fetal Urology guidelines. HN was then gauged using HI, a reproducible, standardized, and dimensionless measurement of renal area. We then calculated average HI for each HN grade.Results. Comparing HI to standard SFU HN grade, average HI is 89.3 for grade I; average HI is 83.9 for grade II; average HI is 73.0 for grade III; average HI is 54.6 for SFU grade IV.Conclusions. HI correlates well with SFU HN grade. The HI serves as a quantitative measure of HN. HI can be used to track HN over time. Versus conventional grading, HI may be more sensitive in defining severe (grades III and IV) HN, and in indicating resolving, stable, or worsening HN, thus providing more information for clinical decision-making and HN management.

scholarly journals QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi197-vi198 ◽  
Author(s):  
Marijke Coomans ◽  
Martin Taphoorn ◽  
Neil Aaronson ◽  
Brigitta Baumert ◽  
Martin van den Bent ◽  
...  
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Scale Item ◽  
Individual Patient Level ◽  
Patient Level ◽  
Related Quality ◽  
The Individual ◽  
The Impact ◽  
Over Time

Abstract BACKGROUND: Health-related quality of life (HRQoL) is an important outcome in glioma research, reflecting the impact of disease and treatment on a patient’s functioning and wellbeing. Data on changes in HRQoL scores provide important information for clinical decision-making, but different analytical methods may lead to different interpretations of the impact of treatment on HRQoL. This study aimed to study whether different methods to evaluate change in HRQoL result in different interpretations. Methods: HRQoL and sociodemographical/clinical data from 15 randomized clinical trials were combined. Change in HRQoL scores was analyzed: (1)at the group level, comparing mean changes in scale/item scores between treatment arms over time, (2)at the patient level per scale/item by calculating the percentage of patients that deteriorated, improved or remained stable on a scale/item per scale/item, and (3)at the individual patient level combining all scales/items. Results: Data were available for 3727 patients. At the group scale/item level (method 1), only the item ‘hair loss’ showed a significant and clinically relevant change (i.e. ≥10 points) over time, whereas change scores on the other scales/items showed a statistically significant change only (all p< .001, range in change score:0.1–6.2). Analyses on the patient level per scale (method 2) indicated that, while a large proportion of patients had stable HRQoL over time (range:27–84%), many patients deteriorated (range:6–43%) or improved (range:8–32%) on a specific scale/item. At the individual patient level (method 3), the majority of patients (86%) showed both deterioration and improvement, while only 1% of the patients remained stable on all scales. Conclusion: Different analytical methods of changes in HRQoL result in distinct interpretations of treatment effects, all of which may be relevant for clinical decision-making. Additional information about the joint impact of treatment on all outcomes may help patients and physicians to make the best treatment decision.

scholarly journals OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii14-iii14
Author(s):  
M Coomans ◽  
M J B Taphoorn ◽  
N Aaronson ◽  
B G Baumert ◽  
M van den Bent ◽  
...  
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Scale Item ◽  
Individual Patient Level ◽  
Patient Level ◽  
Related Quality ◽  
The Individual ◽  
The Impact ◽  
Over Time

Abstract BACKGROUND Health-related quality of life (HRQoL) is often used as an outcome in glioma research, reflecting the impact of disease and treatment on a patient’s functioning and wellbeing. Data on changes in HRQoL scores may provide important information for clinical decision-making, but different analytical methods may lead to different interpretations of the impact of treatment on HRQoL. This study aimed to examine three different methods to evaluate change in HRQoL, and to study whether these methods result in different interpretations. MATERIAL AND METHODS HRQoL and sociodemographical/clinical data from 15 randomized clinical trials were combined. Change in HRQoL scores was analyzed in three ways: (1) at the group level, comparing mean changes in scale/item scores between treatment arms over time, (2) at the patient level per scale/item by calculating the percentage of patients that deteriorated, improved or remained stable on a scale/item per scale/item, and (3) at the individual patient level combining all scales/items. RESULTS Baseline and first follow-up HRQoL data were available for 3727 patients. At the group scale/item level (method 1), only the item ‘hair loss’ showed a significant and clinically relevant change (i.e. ≥10 points) over time, whereas change scores on the other scales/items showed a statistically significant change only (all p<.001, range in change score: 0.1–6.2). Analyses on the patient level per scale (method 2) indicated that, while a large proportion of patients had stable HRQoL over time (range 27–84%), many patients deteriorated (range: 6–43%) or improved (range: 8–32%) on a specific scale/item. At the individual patient level (method 3), the majority of patients (86%) showed both deterioration and improvement, while only 1% of the patients remained stable on all scales. Clustering on clinical characteristics (WHO performance status, sex, tumor type, type of resection, newly diagnosed versus recurrent tumor and age) did not identify subgroups of patients with a specific pattern of change in their HRQoL score. CONCLUSION Different analytical methods of changes in HRQoL result in distinct interpretations of treatment effects, all of which may be relevant for clinical decision-making. Additional information about the joint impact of treatment on all outcomes, showing that most patients experience both deterioration and improvement, may help patients and physicians to make the best treatment decision.

scholarly journals Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression

2018 ◽  
Vol 6 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Ankur M Sharma ◽  
Michael Willcock ◽  
Oliver Bucher ◽  
Thelina Amaratunga ◽  
M Nazir Khan ◽  
...  
Keyword(s):  
Decision Making ◽  
Adjuvant Radiotherapy ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
World Health ◽  
Tumor Treatment ◽  
Institutional Review ◽  
Grade Ii ◽  
Health Organization ◽  
Treatment Window

Abstract Background Pseudoprogression refers to areas of enhancement on MRI postadjuvant chemoradiation that arise as a result of treatment-related effects. Pseudoprogression has been well described with temozolomide-based chemoradiation but has not been studied in the setting of procarbazine, lomustine, and vincristine (PCV) chemotherapy. We reviewed patients treated with PCV to investigate the occurrence of pseudoprogression. Methods Adults diagnosed with World Health Organization grade II or III gliomas between 2010 and 2015 and treated with PCV or temozolomide were identified. Patient, tumor, treatment, and MRI data were retrospectively collected and analyzed. Pseudoprogression was defined as new enhancement seen on MRI within 6 months of completion of adjuvant radiotherapy or concurrent chemoradiation, which improved or remained stable on subsequent scans without therapeutic intervention. If MRI showed areas of new enhancement outside the 6-month post-treatment window, which resolved or remained stable without treatment, or in patients who did not receive adjuvant treatment, it was referred to as “atypical pseudoprogression.” Results Fifty-seven patients were identified. Nine (16%) patients were identified as having pseudoprogression on MRI. Two (4%) of these patients were treated with PCV and 7 (12%) were treated with temozolomide. Seventeen (30%) patients had atypical pseudoprogression: 8 (14%) treated with temozolomide, 8 (14%) treated with PCV, and 1 (2%) treated with both types of chemotherapy. Conclusions We describe the first 2 cases of PCV-related pseudoprogression and 17 cases of atypical pseudoprogression. As the re-emergence of adjuvant PCV occurs in clinical practice, the occurrence of classical and atypical pseudoprogression could have a significant impact on clinical decision making.

A 52-Year-Old Man With Progressive Weakness and Incontinence

2021 ◽  
pp. 194187442110395
Author(s):  
Ayse Altintas ◽  
Ayca Ersen Danyeli ◽  
Subutay Berke Bozkurt ◽  
Sanem Pinar Uysal ◽  
Sergin Akpek ◽  
...  
Keyword(s):  
Decision Making ◽  
Urinary Retention ◽  
Clinical Decision Making ◽  
Treatment Options ◽  
Diagnostic Testing ◽  
Clinical Decision ◽  
Diagnostic Tools ◽  
Progressive Weakness ◽  
Over Time

Here we report a challenging case of a 52-year-old man presenting with subacute constipation, urinary retention, impotence, absent Achilles reflexes, and hypoesthesia in S2-S5 dermatomes. We review the clinical decision-making as the symptoms evolved and diagnostic testing changed over time. Once the diagnosis is settled, we discuss the sign and symptoms, additional diagnostic tools, treatment options and prognosis.

The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making

2006 ◽  
Vol 104 (4) ◽  
pp. 542-550 ◽  
Author(s):  
Andrew A. Kanner ◽  
Susan M. Staugaitis ◽  
Elias A. Castilla ◽  
Olga Chernova ◽  
Richard A. Prayson ◽  
...  
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
World Health ◽  
Allelic Loss ◽  
Who Grade ◽  
Term Survival ◽  
True Value ◽  
Grade Ii ◽  
The Impact

Object Oligodendrogliomas are rare primary brain tumors. They comprise approximately 5 to 33% of all glial tumors but differ from astrocytomas by being associated with a more favorable prognosis, making their correct identification important. Allelic loss of chromosome arms 1p and 19q is found in a substantial subpopulation of tumors with an oligodendroglioma phenotype. Anaplastic oligodendrogliomas with allelic loss of 1p have been associated with chemosensitivity and a longer patient survival period. Methods Oligodendroglial neoplasms were studied using fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissue specimens; reference and target probe sets were used to map the telomeric regions of 1p and 19q. The results were correlated with the clinical characteristics of patients treated at our institution between 1993 and 2003. Data obtained in 96 patients were analyzed. This included 63 patients (65.6%) with World Health Organization (WHO) Grade II oligodendroglioma, 22 (23%) with Grade III oligodendroglioma, and 11 (11.4%) with mixed oligoastrocytoma. Analysis of 1p in patients with pure oligodendroglioma revealed a loss of 1p in 42 patients (49.4%). In 46 of these patients 19q was lost and in 70 (82.3%) there was concordance for combined loss or retention of both 1p and 19q (p < 0.0001). Patients with oligodendroglioma in whom a loss of 1p was present fared significantly better, and this outcome was unrelated to the treatment modality or WHO grade, compared with patients in whom 1p was intact (p < 0.05). Conclusions To the authors’ knowledge, this study includes the largest published series of WHO Grade II oligodendroglioma and 1p analysis. The results suggest that the association between long-term survival and 1p loss in oligodendroglioma is unrelated to treatment. The authors of further prospective studies may better determine the true value of the allelic loss of 1p and its implication for clinical decision making.

scholarly journals Enhanced Visualization of Optimal Cerebral Perfusion Pressure Over Time to Support Clinical Decision Making*

2016 ◽  
Vol 44 (10) ◽  
pp. e996-e999 ◽  
Author(s):  
Marcel J. H. Aries ◽  
Robin Wesselink ◽  
Jan Willem J. Elting ◽  
Joseph Donnelly ◽  
Marek Czosnyka ◽  
...  
Keyword(s):  
Decision Making ◽  
Cerebral Perfusion Pressure ◽  
Cerebral Perfusion ◽  
Clinical Decision Making ◽  
Perfusion Pressure ◽  
Clinical Decision ◽  
Optimal Cerebral Perfusion Pressure ◽  
Over Time

Personality Assessment in Clinical Psychology

2018 ◽  
Author(s):  
Katy W. Martin-Fernandez ◽  
Yossef S. Ben-Porath
Keyword(s):  
Decision Making ◽  
Clinical Psychology ◽  
Personality Assessment ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Self Report ◽  
Assessment Instruments ◽  
Test Taker ◽  
Individual Assessment ◽  
Over Time

Attempts at informal personality assessment can be traced back to our distant ancestors. As the field of Clinical Psychology emerged and developed over time, efforts were made to create reliable and valid measures of personality and psychopathology that could be used in a variety of contexts. There are many assessment instruments available for clinicians to use, with most utilizing either a projective or self-report format. Individual assessment instruments have specific administration, scoring, and interpretive guidelines to aid clinicians in making accurate decisions based on a test taker’s answers. These measures are continuously adapted to reflect the current conceptualization of personality and psychopathology and the latest technology. Additionally, measures are adapted and validated to be used in a variety of settings, with a variety of populations. Personality assessment continues to be a dynamic process that can be utilized to accurately and informatively represent the test taker and aid in clinical decision making and planning.

scholarly journals The impact of mobile technologies on new graduate nurses’ perceived self-efficacy and clinical decision making: A report from a longitudinal study in Western Canada

2017 ◽  
Vol 6 (6) ◽  
pp. 28
Author(s):  
Monique Sedgwick ◽  
Olu Awosoga ◽  
Lance Grigg
Keyword(s):  
Decision Making ◽  
Self Efficacy ◽  
Clinical Decision Making ◽  
Point Of Care ◽  
Clinical Decision ◽  
Mobile Technologies ◽  
Steady Increase ◽  
Pertinent Data ◽  
The Impact ◽  
Over Time

Healthcare environments require practitioners to competently and independently collect pertinent data, select appropriate key resources, prioritize information, solve problems, and make sound clinical decisions. The steady increase of health-related information implies a need for useful, practical Information and Communication Technology (ICT) tools that easily provide nurses’ access to accurate evidence-based information. The purpose of this study was to explore the impact of using mobile technologies at the point of care on new graduates’ perceived clinical decision making ability and associated level of self-efficacy over time. A longitudinal quasi-experimental pre-test/post-test design was used. A trend in the findings of this small study suggests that over time, using mobile technologies at the point of care did not enhance the participants’ perceived clinical decision making ability or self-efficacy in clinical decision making. Notwithstanding, the use of mobile technologies in the practice setting is wide spread. It, however, may be that the transition from student to graduate nurse is a significant enough event that seriously limits the useful influence of mobile devices and their associated applications on clinical decision making ability and self-efficacy.

Sign in / Sign up

Export Citation Format

Share Document